partnering
Summit’s Seglin™ technology platform offers a unique opportunity to probe previously unexploited target space and refractory targets across multiple therapy areas.
Summit aims to exploit the utility of our Seglin™ platform beyond our current internal focus and have opportunities in a number of therapy areas including oncology, metabolic disorders, inflammation, and neurodegeneration. We are seeking partners for discovery and development collaborations and broader strategic alliances.
For further information, please email: info@summitplc.com
